Pasi A. Janne

Pasi Janne leads the thoracic oncology program at Dana-Farber and is considered one of the world's foremost experts on acquired resistance to EGFR-targeted therapies. He characterized key resistance mechanisms to first-, second-, and third-generation EGFR inhibitors, including the C797S mutation conferring resistance to osimertinib. His laboratory works on developing fourth-generation EGFR inhibitors to overcome compound mutations. He has trained dozens of lung cancer researchers and leads multiple early-phase clinical trials.